Dr. Jason Sicklick of Moores Cancer Center at the University of California San Diego talks about the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.
The INTRIGUE study is a Phase 3 clinical trial testing the investigational drug ripretinib (DCC-2618) for patients living with GIST that are no longer on imatinib due to progression or intolerance.
Dr. Breelyn Wilky answering questions on a panel of GIST experts at Life Fest Miami, 2018. Colorado, Clinical Trials & Immunotherapy Dr. Wilky, Director of Sarcoma Translational Research at the University of [...]
How to Make 2/3 = 1 (100%) In a recent discussion about the frequency of mutations in GIST, we noted that the most common mutation is KIT exon 11, which makes up about 2/3 [...]
Pharma Panel: Overview of Promising Trials for GIST "Addressing Key Mechanisms of Tumor Drug Resistance" Deciphera Pharmaceuticals view all Life Fest 2018 Videos
Pharma Panel: Overview of Promising Trials for GIST Blueprint Medicines View all life fest 2018 videos
Executive Director, Norman Scherzer, and Real World Evidence Data Scientist, Dr. Yu Wang, of the Life Raft Group recently attended the ASCO (American Society of Clinical Oncologists) 2018 meeting in Chicago. Dr. Wang describes [...]
On January 4th, 2018 Deciphera Pharmaceuticals, Inc, announced the start of the Phase 3 INVICTUS trial. This randomized trial is for 4th line GIST patients that have failed (or are intolerant) the [...]
By Jennifer Moore, LRG Member I was waiting in line to pick up a new prescription for Gleevec when my husband ran in and told me to forget it. After two surgeries, a year [...]
At the most basic level, cancer patients join clinical trials because of perceived value and perceived cost. In this context, perceived cost refers to more than just financial cost, although that is important. Perceived [...]